Last reviewed · How we verify
Panretin (ALITRETINOIN)
Panretin (generic name: ALITRETINOIN) is a Retinoid [EPC] Small molecule drug developed by Advanz. It is currently FDA-approved (first approved 1999) for Kaposi's Sarcoma Skin Lesions.
Panretin works by binding to retinoic acid receptors in the skin, which helps to slow down the growth of cancer cells.
Panretin, also known as alitretinoin, is a small molecule that acts as a retinoid receptor agonist. It is used to treat conditions such as cutaneous lupus erythematosus, hand dermatoses, and psoriasis.
At a glance
| Generic name | ALITRETINOIN |
|---|---|
| Sponsor | Advanz |
| Drug class | Retinoid [EPC] |
| Target | Retinoic acid receptor beta |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1999 |
Mechanism of action
Think of it like a key fitting into a lock. Panretin is the key that fits into the retinoic acid receptor lock, which helps to turn off the signals that tell cancer cells to grow. This helps to slow down the growth of Kaposi's Sarcoma skin lesions.
Approved indications
- Kaposi's Sarcoma Skin Lesions
Common side effects
- Rash
- Pain
- Paresthesia
- Pruritus
- Edema
- Exfoliative dermatitis
- Skin disorder
Key clinical trials
- A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema (PHASE3)
- Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis (PHASE3)
- Alitretinoin in the Treatment of Chronic Hand Eczema (PHASE3)
- Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis (PHASE3)
- Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis (PHASE3)
- Dupilumab in Severe Chronic Hand Eczema (PHASE2)
- Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19 (PHASE2)
- Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Panretin CI brief — competitive landscape report
- Panretin updates RSS · CI watch RSS
- Advanz portfolio CI
Frequently asked questions about Panretin
What is Panretin?
How does Panretin work?
What is Panretin used for?
Who makes Panretin?
What is the generic name of Panretin?
What drug class is Panretin in?
When was Panretin approved?
What development phase is Panretin in?
What are the side effects of Panretin?
What does Panretin target?
Related
- Drug class: All Retinoid [EPC] drugs
- Target: All drugs targeting Retinoic acid receptor beta
- Manufacturer: Advanz — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Kaposi's Sarcoma Skin Lesions
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing